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Abstract 
While several randomised control trials (RCTs) have evaluated the use of fractional exhaled 
nitric oxide (FeNO) to improve asthma outcomes, none used FeNO cut-offs adjusted for 
atopy, a determinant of FeNO levels. In a dual centre RCT, we assessed whether a treatment 
strategy based on FeNO levels, adjusted for atopy, reduces asthma exacerbations compared 
with the symptoms-based management (controls). 
 
Children with asthma from hospital clinics of two hospitals were randomly allocated to 
receive an a-priori determined treatment hierarchy based on symptoms or FeNO levels. There 
was a 2-week run-in period and they were then reviewed ten times over 12-months. The 
primary outcome was the number of children with exacerbations over 12-months.  
 
Sixty-three children were randomised (FeNO=31, controls=32); 55 (86%) completed the 
study. Although we did achieve our planned sample size, significantly fewer children in the 
FeNO group (6 of 27) had an asthma exacerbation compared to controls (15 of 28), p=0.021; 
number to treat for benefit=4 (95%CI 3-24). There was no difference between groups for any 
secondary outcomes (quality of life, symptoms, FEV1). The final daily inhaled corticosteroids 
(ICS) dose was significantly (p=0.037) higher in the FeNO group (median 400µg, IQR 250-
600) compared to the controls (200, IQR100-400).  
 
Taking atopy into account when using FeNO to tailor asthma medications is likely beneficial 
in reducing the number of children with severe exacerbations at the expense of increased ICS 
use. However, the strategy is unlikely beneficial for improving asthma control. A larger study 
is required to confirm or refute our findings.  
Key Words: FeNO, asthma, pediatrics, atopy.
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Introduction 
Asthma is one of the most common chronic disease in children, accounting for 121 to 212 % 
of hospitalisations worldwide.3 Preventing exacerbations, particularly severe exacerbations 
and hospitalisations, is one goal of good asthma management. The second component in 
asthma management is monitoring of asthma control (by subjective and objective measures).4-
6 Subjective measures usually involve a series of questions used for clinical assessment, diary 
cards and quality of life (QoL) questionnaires. Traditional objective methods include peak 
flow, spirometry and degree of airway hyper-responsiveness.7 Newer, and arguably more 
sensitive, methods include measurement of airway inflammation such as airway cellularity in 
induced sputum or fractional exhaled nitric oxide (FeNO).8 
 
Induced sputum has been shown to be beneficial in adults9 but is relatively labour intensive 
and has limited availability, particularly in children. In contrast, FeNO is easily measured in 
children and confers some advantage over sputum eosinophils.7 Thus its universal use has 
been advocated by some.10 However, our Cochrane review found that the role of utilising 
exhaled nitric oxide to tailor the dose of inhaled corticosteroids cannot be routinely 
recommended for clinical practice at this stage and its role in monitoring asthma remains 
uncertain.11  
 
There are 7 published12-18 randomised controlled trials (4 children/adolescents and 3 adults) 
that have assessed whether adjustment of asthma treatment in accordance to FeNO levels is 
superior to ‘usual management’. None of the 4 paediatric studies13-15,17 used asthma 
exacerbations as the primary outcome, while three adult papers did.12,16,18 Meta-analysis 
revealed there was no significant difference in exacerbations between the FeNO group 
compared to controls.11 In adults, the daily dose of inhaled corticosteroids (ICS) at end of 
study was decreased in the FeNO group compared to controls (mean difference -450 µg 
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(95%CI -677, -223; p<0.0001). However in children, adjusting medications according to 
FeNO levels resulted in a significant increase of mean daily ICS dose (mean difference 140 
µg, 95%CI 29, 251; p=0.014).  
 
Thus, controversy remains of the benefit or otherwise on the benefits of use of FeNO for 
routine asthma management.19 Further, the appropriate FeNO cut-off remains elusive despite 
recent recommendations.20  FeNO levels are dependent on atopy21,22 and none of the RCTs 
have considered atopic status in FeNO levels when medications were adjusted. We conducted 
a dual-centre RCT with 3 unique features; exacerbation was our primary outcome, atopy was 
considered in the FeNO strategy when medications were tailored and lastly, only FeNO levels 
were used (discounting symptoms) in the FeNO strategy group.  
 
Our aim was to determine if adjustment of asthma medications based on FeNO levels 
(compared to management based on clinical symptoms) reduces severe exacerbations in 
children with asthma. We also examined the effect on two asthma control measures (diary 
card and QoL). We hypothesised that a childhood asthma management strategy based on 
FeNO and atopy status reduces exacerbations requiring rescue oral corticosteroids and/or 
hospitalisations.  
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Methods 
Subjects 
Inclusion criteria: Children aged >4 years with persistent asthma,4 prescribed anti-
inflammatory asthma treatment, and receiving their care primarily through our clinical service 
at Royal Children’s Hospital, Brisbane or Prince of Wales Hospital, Hong Kong. We 
excluded children who had underlying cardio-respiratory illness such as bronchiectasis or 
tracheomalacia, inability to take ICS or long acting beta-2-agonists (LABA) or had previous 
poor adherence to medications (as documented in clinic notes).  
 
The study was approved by the ethics committee at Royal Children’s Hospital, Brisbane and 
Prince of Wales Hospital, Hong Kong. Informed and written consent was obtained from all 
parents of participants. The trial is registered with the Australia New Zealand Clinical Trials 
Registry (ACTRN012605000321640) 
 
Protocol 
Children and their parents were approached when they attended a routine clinic visit. After 
consent and recruitment, we recorded the child’s demographics, run-in measurements and 
their technique of taking their medications checked by an asthma educator-nurse (HP and 
CA). A 2-week run-in period was undertaken to ensure stability. During this period, the 
children were maintained on their current treatment. If they were unstable (based on clinician 
review and diary cards) their medications were adjusted by their treating physician and a 
further run-in period was undertaken. At the end of the run-in, the child was randomised and 
initial measurements were obtained. These were spirometry, asthma QoL23,24, FeNO, skin 
prick test and commencement of asthma symptom diary25.  
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The children were randomised (stratified by age [<6 or ≥ 6 years] and site [Brisbane or Hong 
Kong]) to one of two strategies (a) management based on clinical symptoms (control group) 
or (b) management based on FeNO levels (FeNO group). Randomisation was done by an 
independent individual off-site through computer generation sequence list in permuted 
random blocks of 4 to 6. Allocation was fully concealed using opaque covers.  
 
Patients were followed up for 12-months, with monthly visits for the first 4 months and every 
2 months thereafter. Children attended at the same time of day on each occasion. At each visit 
we assessed patients with FeNO, spirometry before and after 400ug inhaled salbutamol, the 
Paediatric Asthma Caregiver QoL Questionnaire (PACQLQ)24 and Paediatric Asthma QoL 
Questionnaire (PAQLQ)23 (in children aged ≥7 years), symptom diary cards25 and review by 
paediatric respiratory physician. FeNO measurements were performed before spirometry. All 
investigations were standardised. Decisions to adjust therapy (in accordance to hierarchy of 
medication treatment) were made by investigators who were blinded to the participant’s 
FeNO if randomised to clinical symptoms group or symptoms scores if randomised to FeNO 
group. The asthma management strategy was not revealed to the children and parents. 
Adherence was monitored by checking their medications (supplied for the entire study 
period). Cumulative doses of ICS for each child was calculated based on the child’s daily 
dose over the study period and expressed per child-year. 
 
Hierarchy of medication treatment  
The hierarchy (Table 1) was modified from the Australian National Asthma Council 
guidelines4 and GINA guidelines.5 In the control group treatment decisions were made on 
symptoms as recorded on the asthma symptom diary card. Control was considered inadequate 
and treatment increased if scores increased by ≥15% since the previous visit. Treatment was 
stepped down if the child’s scores totalled < 10 in recent week. Reasons for using these cuts 
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offs are described below. In the FeNO group, adjustment of treatment was based on FeNO 
level and atopic status. If FeNO was elevated, therapy was stepped up according to the 
predetermined hierarchy of management (Table 1). If FeNO was low for 2 consecutive visits, 
medications were stepped down.  Elevated FeNO was defined (based on a cohort study26 in 
Perth, Australia) as ≥10ppb in children with no positive skin prick test (SPT), ≥12ppb in 
children with one positive SPT, and ≥20ppb in children with ≥2 positive SPT. 
  
Details of methods 
Allergens used for SPT in Brisbane were Alternaria mould, cat hair, cockroach mix, dust mite 
DPT, couch grass, and grass mix #7 (Hollister-Stier, WA, USA). Negative (diluents) and 
positive (histamine) controls were also used. The allergens used in Hong Kong were 
Dermatophagoides pteronyssinus and Dermatophagoides farinae house dust mites, cat and 
dog dander, mixed American and German cockroaches, mixed ragweed, grass pollens, and 
tree pollens, and mixed moulds (Penicillium notatum, Alternaria tenuis, Aspergillus 
fumigatus, and Hormodendrum cladosporioides). Atopy was defined as wheal ≥3mm larger 
than the negative control and larger than the histamine.  
 
FeNO was measured with a chemiluminescence analyser (Sievers NOA 280i, Colorado, 
USA) with children exhaling at 0.05L/second for >4 seconds in order to obtain a stable NO 
value for > 2 seconds, in accordance to ATS/ERS guidelines.27 Exhalations were repeated 
until three measurements were within 5% of the mean. Spirometry was performed using ATS 
criteria and % predicted based on local age and sex matched reference values in Hong Kong28 
and Eigen29 from Australian data (Hibbert30 (children ≥8 years) in Brisbane. 
 
As multiple clinicians were involved in the on-going clinical care of the children, it was 
necessary to standardise clinical management. Thus, we utilised a validated daily diary 
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asthma card.25  The diary (completed every day) consisted of 4 questions (Table 2) with a 6-
point scale, with a score of 6 reflecting worse symptoms. To obtain the composite scale, the 
score per question is averaged thus providing a score of 0-6 per day. The asthma scores were 
quantified by entering the numerical answer into a spreadsheet and average obtained for the 
previous month. The cut offs used for altering medications are based on the following: 
Santanello et al’s paper31 had described that children had well controlled asthma if their 
scores per day was <1/day (mean 0.56, SD 0.67) per week. For the week’s total score taking 
1.96 times the SD, the upper limit equates to 9.2/week. Hence we considered children were 
well controlled if their total weekly score was <10. Our previous paper32 on asthma had also 
similar results with respect to the scores when well. For the 15% change representing 
instability, this was based on 1.96 times the standard deviation of the median change in the 
children with unstable asthma, as described by the authors of the asthma diary scale in their 
paper for discriminant validity between stable and unstable children.31 
 
Outcome measures 
The primary outcome (stated a-priori in our trial registration) was number of children with 
severe exacerbation defined as respiratory events requiring a course of oral corticosteroids 
with or without hospitalisation. Exacerbation treatment was determined by the primary 
paediatrician or respiratory physician that was blinded to the child’s allocated group. In 
accordance to as ATS guidelines33 (that was not available at time of study design), 
requirement for oral corticosteroids or hospitalisation represents a severe exacerbation. 
Secondary outcomes were: FEV1 %predicted, asthma QoL, symptom scores and dose of ICS 
at end of study. ICS dose was expressed as budesonide-equivalent dose, with fluticasone 
considered twice the dose of budesonide. 
 
Statistical analysis  
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Sample size was calculated based on Green et al9 study, which was the only study available at 
the time the study commenced.  In Green et al’s9 study the reduction in exacerbation in 
sputum-managed group was 31% less than the control arm (109 exacerbations in 26 subjects). 
To obtain a 30% reduction in exacerbations in the FeNO group compared to controls (3 per 
person year), a sample size of 43 per group was required for 90.5% power at 0.05 significance 
level. We planned to recalculate sample size based on findings on the first 60 children 
recruited. However, as the first preliminary analysis showed a difference between groups, the 
study was terminated prior to reaching the sample size. 
 
Descriptive statistics were used to summarise the demographic characteristics of the patients. 
Data that had a normal distribution were described using means and SD; medians and inter-
quartile ranges (IQR) were used otherwise. Fisher’s exact tests were employed for categorical 
data. Kruskal-Wallis analyses were used for group comparisons. Two-tailed p values of < 
0.05 were considered significant. All statistical calculations were analysed using SPSS 
Version 13. Intention to treat analyses was used, and children who dropped out were assumed 
to have no exacerbations. 
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Results 
We recruited 65 children between February 2006 to April 2008; of whom 63 were 
randomised. Two children were not randomised; one child could not be stabilised during the 
run-in despite 3 visits, and one withdrew due to family circumstances. Of the 63 children who 
were randomised, only 2 children required adjustment of their medications during the run-in 
period to stabilise their asthma and therefore the 2-week run-in was repeated. By chance, both 
were randomised to the FeNO arm. During the follow-up period, 8 children withdrew (4 from 
each arm), leaving 27 children in FeNO management group and 28 in clinical symptom group 
(Figure 1). No participant withdrew because of poor asthma control. The two groups were 
well matched at baseline (Table 3) for demographic and clinical features, other than symptom 
score that was significantly higher in the controls. 
 
Exacerbations 
None of the children were hospitalised during the study period. Compared to the control 
group, significantly less children in the FeNO group had ≥1 exacerbation over the study 
period (6 children in FeNO group versus 15 in controls, p=0.017) (Figure 2). The number 
needed to treat (NNT) to prevent one child from having any exacerbation in 12 months was 4 
(95%CI 3, 24). However, although the rate of exacerbations was lower in the FeNO group 
(0.39 per person-year) compared to controls (0.78 per person-year), the difference did not 
reach statistical significance (p=0.102). When the groups were sub-analysed into those with 
≥2 exacerbations per year, we also found no significant difference between the groups (3 
children in FeNO group versus 5 children in control group, p=0.251). 
 
Other outcome measures 
Asthma QoL scores, FEV1 %predicted and FeNO values were not significantly different 
between the groups at the end of, or at any time point of the study (p range from 0.08 to 
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0.829) (figure 3). Asthma diary scores were also similar between the groups (p value range 
0.06 to 0.928). Asthma symptom scores at final visit were: FeNO group (median 0, IQR 0, 
8.75) and controls (median 2.5, IQR 0, 17.25, p=0.394).  
 
Inhaled corticosteroid (ICS) dose 
At end of study (12-months), the final daily ICS dose was significantly (p=0.037) higher in 
the FeNO group (median 400 μg, IQR 250, 600) compared to the control group (median 200 
µg, IQR100, 400). However, when the difference between final and baseline dose was 
considered, there was no difference (p=0.139) between the groups (FeNO group: median 0, 
IQR (-175, 100); control group: median of -200, (IQR -300, 100).  With respect to the 
cumulative dose per child-year, the total median dose was significantly higher in the FeNO 
group (168,000µg, IQR 93,000, 210,000) compared to the control group (105,000µg, IQR 
73,500, 156,000), p=0.016.
 12 
Discussion 
Our dual centre RCT evaluated an asthma management strategy based on FeNO (with atopy 
considered) compared to usual treatment (controls, based on asthma guidelines). We found 
that significantly fewer children in the FeNO group had severe asthma exacerbations 
compared to children managed by symptom control (diary). However, while the exacerbation 
rate was lower in the FeNO group (compared to controls), this did not reach statistical 
significance (which is likely related to the lack of power). Children in the FeNO group had 
significantly higher ICS use (daily dose by the end of the 12 months and accumulative dose) 
compared to the control group, but the difference between end and start of trial was not 
significantly different between groups. Also asthma control factors (asthma and cough diary 
scores, QoL) were similar between groups.  
 
While there are now several published RCTs13-15,17 that evaluated whether using FeNO to 
adjust asthma medications is superior to using symptoms alone, our study has 3 features that 
likely accounts (at least in part) for our different results differ from previous published RCTs 
in children/adolescent. These features are (a) our study is the sole study that adjusted FeNO 
cut-offs based on atopy, (b) none of the previous paediatric studies used asthma exacerbations 
as the primary outcome, and (c) the FeNO strategy only utilised FeNO levels to adjust 
treatment.  
 
There are 4 published RCTs in children that have evaluated the benefit of a FeNO-based 
strategy in adjusting medications for asthma.13-15,17  None had shown any significant benefit 
of using FeNO compared to controls with respect to exacerbations but none of the studies 
used exacerbation as their primary end-point, used FeNO levels solely in intervention arm or 
adjusted according to atopy status. In contrast, the adult-based studies12,16,18 used 
exacerbations as their primary outcome, but none showed any benefit in reducing asthma 
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exacerbation. Also, none of these adult studies adjusted FeNO based on atopy. De Jongste et 
al15 assessed daily FeNO telemonitoring in 151 children with atopic asthma over 30 weeks 
with treatment (adjusted every 3 weeks). Both control and FeNO groups showed an increase 
in symptom-free days, improvement of FEV1 and QoL, and a reduction in ICS dose, with no 
significant difference between the groups. Fritsch et al13 concluded that therapy aimed at 
lowering FeNO in 47 children with asthma, improved parameters of small airway function but 
was did not improve clinical markers of asthma control. At the end of the study (6 months) 
children in the FeNO group had higher median daily doses of ICS in comparison to the 
control group (316 µg versus 241 µg) but reported as not significant.13 Pijnenburg et al17 
showed that titrating steroids based on FeNO levels in children did not result in higher steroid 
doses and improves airway hyper-responsiveness and markers of airway inflammation, but 
there was no difference in exacerbations or asthma symptoms between groups. In Szefler et 
al’s study14 (n=546 adolescents), the mean number of days with asthma symptoms (primary 
outcome), pulmonary function and asthma exacerbations also did not differ between the 
groups. Participants in the FeNO group received higher doses of ICS (difference 119 µgm per 
day, 95%CI 49 to 189) than controls. All but one study17 reported no difference in FeNO 
levels between the groups at end point. Pijnenburg et al17 reported no change from baseline in 
the FeNO group, but the symptom group had an increase of 32% from baseline levels. 
 
Our study is the first RCT on FeNO-based asthma management evaluation that have 
considered the presence or severity of atopy in their algorithm of management. Our FeNO 
cut-off levels were adjusted in accordance to severity of atopy defined on SPT. We speculate 
that this is one of the reasons why our study showed a benefit compared to the others which 
did not show a difference in exacerbations between groups. Raised FeNO in children has been 
associated with atopy with or without respiratory symptoms.21,22 FeNO values in people with 
atopy can be as high as 54ppb compared to non-atopic people even in the absence of any 
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disease.34 However our inclusion criteria was different as not all the children in our study was 
atopic whereas 'Atopic asthma' was an inclusion criterion for Pijnenburg et al17 as defined as 
RAST class 2 or higher for at least one airborne allergen ever. Similarly all children in Fritsch 
et al13 and de Jongste15 had an inclusion criteria of positive skin prick test or RAST. Szefler et 
al14 attended to skin prick tests with 88% testing positive to at least 1 of 15 allergens. Of the 
adult studies, Shaw and colleagues16 reported that some of their participants were atopic (62% 
in FeNO group, 70% in control group). Powell and colleagues18 also reported participants 
being atopic (75.2% in FeNO group, 76.2% in control group). Whereas Smith et al12 did not 
describe whether their subjects were atopic or not. The cut-offs we used for adjustment was 
low but this was intended in the context that children already on ICS would have low FeNO 
levels and we were guided by the sole paper that reported FeNO levels and atopy in children 
at the time our study commenced. It could be argued that adjustment for age, gender, size and 
ethnicity should also be taken into account. However we considered this unnecessary as it 
would have been not feasible to adjust for so many factors. Further age and ethnicity are 
lesser  predictors for FeNO levels (compared to atopy)35 and our study was a RCT and groups 
were well matched (table 3).  
  
In our study, children in the FeNO group had significantly higher ICS doses than controls. 
This is similar to 2 other published paediatric studies13,14 but dissimilar to two others.15,17 
Although, there was no significant difference between groups for ICS dose in the Pijnenburg 
et al17 study, children in that study had a high mean daily dose of ICS at the final visit (FeNO 
group= 935µg (SD 656); control group= 910 µg (SD 678)). The cumulative dose of ICS at 
end of study was also significantly higher in the FeNO group. 
 
The cut offs of FeNO utilised for stepping up or down therapy also differed among previous 
published studies (ranging from 15 to 30 ppb). Recently published ATS guidelines20 suggests 
 15 
that FeNO levels in children <20ppb is less likely to respond to corticosteroids (CS) and 
levels >35ppb in children will be responsive to CS. These guidelines also recommend that cut 
points are utilised rather than reference values.20 Furthermore, in the RCT’s conducted to date 
the algorithms used are not based on ASthma TReatment ALgorithm (ASTRAL) studies.36   
Jacinto et al37 conducted a systematic review examining the reference/normative values and 
individual factors effecting FeNO levels. They concluded that the formulation of reference 
values should be “based on a preset physiological model with endogenous and stable 
factors”.37  
 
We used a cut-off that was very low as, when  our protocol was designed in 2005, there was 
little data to guide and we based our  cut off values on the only data available in large healthy 
Australian cohort.21 Despite this limitation, we believe that the concept of atopy adjustment 
for FeNO levels is important given that our study was dual-centred with significant 
differences found between the two treatment strategies.  Recently, “personal best” has been 
suggested as the cut-off point38 but defining this level may not be straight forward.  
 
Current asthma guidelines differ with respect to steps in therapy and none of the current 
guidelines currently recommend using FeNO. In designing our hierarchy of treatment we 
considered feasibility, the Australian approach and health system (at the time the study was 
designed). Thus the steps used in our study are neither aligned to steps in the BTS or USA 
guidelines.5,6 Also, we used a validated symptom score diary to assure a consistent 
interpretation of symptoms ie. to semi-objectively quantify asthma symptoms as opposed to 
true ‘usual care’. The change of scores to up and down-tailor medications is beyond the 
realms of ‘usual care’ but arguably our method was more robust as usual care would be 
difficult to define when several physicians across 2 centres were involved in the care of the 
children. Further use of a symptom scoring system allowed blinding of the physician. 
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Nevertheless, our ‘control’ strategy did not represent ‘placebo’ as the children were still 
actively managed. This possibly dilutes the effect of the utility of using FeNO.  
 
Further to the above, our study has several additional limitations. Firstly, we ceased 
recruitment after 2.3 years for feasibility reasons, before reaching our planned sample size, as 
preliminary analysis had shown a difference between the groups. This is a major limitation as 
we did not pre-specify stopping rules in our trial register. We did not perform post-hoc power 
analyses for equivalence for the outcomes where there were no difference between groups, in 
line with current recommendations on post hoc analyses.39  
 
Secondly, although the children, parents and physician were unaware of the group allocation, 
the authors (HP & CA) who performed the FeNO measurements and calculated the scores 
from the parents’ dairy cards were not blinded. Thirdly, we did not ask the parents or children 
after the trial which group they thought they were in, so we were unable to test participant 
masking. Fourthly, although the randomisation sequence was externally generated and 
different block sizes were used, there is small chance of selection bias in our study. Routinely 
in practice decisions regarding treatment are certainly more complex than our simple 
algorithm, consequently our study did not compare ‘usual care’.  
 
Despite the favourable results in number of patients experiencing asthma exacerbations in the 
12 month follow-up period, the other asthma outcomes measured that reflect asthma control 
asthma QoL and symptoms) showed no difference between groups.  A decrease in 
exacerbation rates from baseline in both groups could be possibly explained by the 
Hawthorne effect.  The discordance between asthma control and exacerbations is increasingly 
appreciated.40,41 While exacerbations are an important outcome, arguably subjective measures 
of asthma control are also important. Thus, although our findings demonstrate that monitoring 
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FeNO is useful in reducing exacerbations, it is likely not beneficial in all children. It is 
possible that it is most beneficial to children who have frequent exacerbations. The non 
beneficial effect on asthma control is consistent in all published paediatric studies to date.13-
15,17 
 
In spite of the limitations of our study, we believe that our study is important as this is the first 
RCT on FeNO that has taken atopy status into account. We conclude that taking atopy into 
account when using FeNO to tailor asthma medications is likely beneficial in reducing the 
number of children with severe exacerbations. This occurred at the expense of significantly 
higher ICS doses. However, the strategy is unlikely beneficial for improving asthma control 
and a larger study that addresses the limitations presented above, is required to confirm or 
refute our findings. 
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Figures 
Figure 1:  Consort Flow chart 
 
Figure 2: Cumulative asthma exacerbations in Clinical Symptoms group (controls) and FeNO 
group.  
Graph shows FeNO group had smaller cumulative number of asthma exacerbations over study 
period when compared to clinical symptoms group. 
 
Figure 3: FeNO in ppb of the two groups during the study period. 
Figure shows FeNO levels in ppb (median, IQR) over the study period between the 2 
strategies (Run-in measurement is prior to commencing run-in period and initial measurement 
after run-in). There was no statistical significance between the groups at each time point. 
 
Figure 4: FEV1 % predicted pre-bronchodilator in the two groups during the study period. 
There was no statistical significance between the groups at each time point. 
 
Figure 5: Asthma Quality of Life scores in the two groups during the study period. There was 
no statistical significance between the groups at each time point. 
 
